News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
New Tools for Treating Advanced Retinal Degenerations Developed by Penn Vet Researchers
Researchers at Penn Vet have developed four novel DNA promoters.
Moderna’s RSV Vaccine Receives Expanded FDA Approval
The FDA has expanded approval for Moderna's mRNA-based RSV vaccine based on Penn IP.
Dr. Jim Wilson’s Gene Therapy Work with Gemma Biotherapeutics Profiled by the Philadelphia Inquirer
Gemma Biotherapeutics was co-founded in 2024 by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Cerespectus and Vasowatch Join HiveBio’s Inaugural Cohort
HiveBio has selected its inaugural cohort of underrepresented biotech founders.
Cerespectus Accepted into Science Center’s Capital Readiness Program
Cerespectus was co-founded by Bryan Pukenas, MD, Associate Professor of Radiology in Penn Medicine.
MavriX Bio Announces FDA Clearance for Gene Therapy Trial
MavriX will initiate a clinical trial of a gene therapy for Angelman syndrome.
Capstan Therapeutics Begins Phase 1 Trial of CAR-T Therapy for Autoimmune Disease
Capstan Therapeutics, a biotechnology company spun out of Penn, has initiated its Phase 1 trial of an in vivo CAR-T therapy.
REGENXBIO’s Gene Therapy Updates for Hunter Syndrome and DMD
REGENXBIO was co-founded by James M. Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director's Professor in Penn Medicine.
Vivodyne Raises $40 Million to Advance Human Tissue Testing Platform
Vivodyne was co-founded by Dan Huh, PhD, Professor of Bioengineering in Penn Engineering and CEO Andrei Georgescu.,
Research at Penn Report Highlights the Global Impact of Penn’s Research
Penn has over 5,000 research faculty spanning 200+ centers.